 AI + Biotech: Why This Segment Is Heating Up Right Now The last 30 days show an interesting picture: the audience of ASI Biont is growing, and the main surge comes from the AI-biotech startup segment. Rejections are only 13.8%, meaning people are not coming by chance but are purposefully searching for automation tools. Why is this logical? Biotech startups (especially at early stages) are drowning in routine: research monitoring, data processing, approvals, reports, email correspondence with partners. Teams of up to 50 people are forced to spend up to 40% of their time on operations that do not require their expertise. ASI Biont AI agents cover exactly this: — autonomous email marketing and outreach — data analytics and cohort analysis — news and trend monitoring — code review and repository management — legal document review No promo code — each new user gets 1500 tokens to start, to try and integrate agents into their processes. → https://asibiont.com/